Corporate Events

ZACROS Corporation, Board Meeting, Jul 10, 2025. Agenda: To consider to dispose of treasury stock as restricted stock.

From April 1, 2025 to June 30, 2025, the company has repurchased 202,600 shares, representing 1.09% for ¥770.78 million. With this, the company has completed the repurchase of 299,600 shares, representing 1.62% for ¥1,180.04 million under the buyback announced on February 6, 2025.

ZACROS Corporation, Board Meeting, May 20, 2025. Agenda: To consider and approve change of representative directors and appointment of the candidates for directors; and to consider any other matters.

ZACROS Corporation announced dividend for the fiscal year ended March 31, 2025 and provided dividend guidance for the second quarter-end and fiscal year-end ending March 31, 2026. For the fiscal year end 2025, the company announced dividend of JPY 57.00 per share compared to previously paid dividend of JPY 42.00 per share. Scheduled date to commence dividend payments: June 23, 2025. For the quarter, the company expects dividend of JPY 67.00 per share compared to previously paid dividend of JPY 53.00 per share. For the year-end, the company expects dividend of JPY 67.00 per share compared to previously dividend of JPY 57.00 per share last year.

ZACROS Corporation provided consolidated earning guidance for the year ending March 31, 2026. For the year ending March 31, 2026, the ZACROS Group projects consolidated net sales of ¥157,000 million, a 4.2% increase over fiscal 2025. Operating income is expected to rise slightly to ¥10,200 million, an increase of 0.8%. As a result, profit attributable to owners of the parent is projected to be ¥7,500 million, a 14.8% increase year on year. Net income to be ¥406.75 per share.

ZACROS Corporation, Annual General Meeting, Jun 20, 2025.

From February 6, 2025 to March 31, 2025, the company has repurchased 97,000 shares, representing 0.52% for ¥409.26 million. With this, the company has completed the repurchase of 97,000 shares, representing 0.52% for ¥409.26 million under the buyback announced on February 6, 2025.

ZACROS Corporation announced that they will report fiscal year 2025 results on May 08, 2025

ZACROS Corporation announced that the Product Development Department, R&D Center, will be reorganized into two departments: "Product Development Department-1" and "Product Development Department-2". This reorganization aims to strengthen development from market and customer perspectives.

ZACROS Corporation announced that the following organizational and personnel changes have been decided. Tomoyuki Sasaki, current position is Executive Officer, Division Manager of Medical Solutions Division, Wellness Business Unit, /Chief Manager of BioPhaS Department, /Chief Manager of IVD Department, New Position is Executive Officer, Division Manager of Medical Solutions Division, Wellness Business Unit, /Chief Manager of IVD Department. Michinori Yoneyama, Current Position is Chief Manager of Product Development Department, R&D Center, New Position is Chief Manager of Product Development Department-1, R&D Center. Yukihiro Kyoden’s Current Position is Chief Manager of Adhesive Solutions, Department, Advanced Materials Division, Electronic Materials Business Unit, New Position is Chief Manager of Product Development Department-2, R&D Center. Kenichi Nakano’s Current Position is Deputy Chief Manager of Nabari Plant, Pharmaceutical & Medical Packaging Division, Wellness Business Unit, New Position is Chief Manager of Nabari Plant, Pharmaceutical & Medical Packaging Division, Wellness Business Unit. Shingo Suzuki’s Current Position is Chief Manager of Mie Plant, Medical Solutions Division, Wellness Business Unit, New Position is Chief Manager of BioPhaS Department, Medical Solutions Division, Wellness Business Unit. Hirotaka Ikeda’s Current Position is Manager of Sustainable Packaging, Development Group, Product Development, Department, R&D Center, New Position is Chief Manager of Mie Plant, Medical Solutions Division, Wellness Business Unit. Yuusuke Kikumoto’s Current Position is Deputy Chief Manager of Adhesive Solutions Department, Advanced Materials Division, Electronic Materials Business Unit, New Position is Chief Manager of Adhesive Solutions Department, Advanced Materials Division, Electronic Materials Business Unit. Nobuaki Kondou’s Current Position is Chief Manager of Nabari Plant, Pharmaceutical & Medical Packaging Division, Wellness Business Unit, New Position is Specialist of Pharmaceutical & Medical Packaging Division, Wellness Business Unit.

ZACROS Corporation announced that it has entered into Business Alliance Agreement with TAUNS Laboratories Inc. for the development and manufacture of components for POCT devices. Under this strategic business alliance, will provide biochip technology for TAUNS's next-generation POCT device they are developing, and work to develop innovative diagnostic products for the global market. Through this alliance, TAUNS expects to improve the functionality and expand the application range of their next-generation POCT device, while expect to gain important adoption results for biochip business. At the same time, this alliance will also include joint development to improve the production efficiency and quality of TAUNS's current rapid diagnostic kits for infectious diseases. This matter will have no impact on company's performance at this time. If it is found to have a significant impact, will disclose it promptly.

ZACROS Corporation, Board Meeting, Feb 06, 2025. Agenda: To repurchase the Company's treasury stock in line with the Company's Articles of Incorporation.

Fujimori Kogyo Co., Ltd. (TSE:7917) announces a share repurchase program. Under the program, the company will repurchase up to 500,000 shares, representing 2.69% of the outstanding shares (excluding the treasury shares) for ¥2,000 million. The purpose of the program is to implement a flexible capital policy aligned with changes in its business environment. The repurchase program is valid till September 30, 2025. As of December 31, 2024, the company had 18,607,448 issued shares (excluding treasury stock) and 660,312 shares in treasury.

ZACROS Corporation, ¥ 10.0, Cash Dividend, Mar-28-2025

On October 31, 2024, Revorf Co., Ltd. closed the transaction. The company has received ¥250.02 million in its second and final tranche closing and received a total of ¥300 million in the transaction. The tranche includes participation from new investor Real Tech Fund No. 1, a fund co-managed by RealTechJapan LLC. and UntroD Capital Japan Co.,Ltd. and other investors.